Stryker Corporation $SYK Shares Sold by Evelyn Partners Asset Management Ltd

Evelyn Partners Asset Management Ltd cut its stake in Stryker Corporation (NYSE:SYK) by 11.2% in the fourth quarter, HoldingsChannel reports. The fund owned 28,759 shares of the medical technology company’s stock after selling 3,610 shares during the period. Stryker accounts for approximately 2.4% of Evelyn Partners Asset Management Ltd’s investment portfolio, making the stock its 11th largest holding. Evelyn Partners Asset Management Ltd’s holdings in Stryker were worth $10,108,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. Evelyn Partners Investment Management Europe Ltd lifted its holdings in Stryker by 4.8% in the fourth quarter. Evelyn Partners Investment Management Europe Ltd now owns 2,938 shares of the medical technology company’s stock valued at $1,033,000 after acquiring an additional 134 shares during the period. Evelyn Partners Investment Management LLP lifted its holdings in Stryker by 4.7% in the fourth quarter. Evelyn Partners Investment Management LLP now owns 267,314 shares of the medical technology company’s stock valued at $93,953,000 after acquiring an additional 12,014 shares during the period. Barclays PLC lifted its holdings in Stryker by 25.8% in the fourth quarter. Barclays PLC now owns 1,168,656 shares of the medical technology company’s stock valued at $410,748,000 after acquiring an additional 239,650 shares during the period. Aigen Investment Management LP lifted its holdings in Stryker by 188.2% in the fourth quarter. Aigen Investment Management LP now owns 3,375 shares of the medical technology company’s stock valued at $1,186,000 after acquiring an additional 2,204 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in Stryker by 1,925.0% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 454,965 shares of the medical technology company’s stock valued at $159,907,000 after acquiring an additional 432,498 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Trading Up 2.1%

Shares of SYK stock opened at $312.14 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The company has a market cap of $119.66 billion, a price-to-earnings ratio of 36.13, a PEG ratio of 1.97 and a beta of 0.78. The stock has a 50 day simple moving average of $316.40 and a 200-day simple moving average of $343.97. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the company earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities research analysts expect that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio is presently 40.74%.

Insider Transactions at Stryker

In other news, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This represents a 28.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 323,264 shares of company stock valued at $100,659,489 in the last three months. 4.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research analysts have issued reports on SYK shares. Canaccord Genuity Group decreased their price target on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price target on Stryker in a report on Friday, May 1st. Evercore set a $355.00 price target on Stryker in a report on Friday, May 1st. UBS Group decreased their price target on Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a report on Tuesday, March 17th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $361.00 price target on shares of Stryker in a report on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and an average price target of $395.33.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.